Search
Watson Biologics: Amends Exclusive Sublicense Agreement to Extend Microecological Health Technology to Non-Patient Areas
2025-07-30 /
Read about 0 minute
Author：小编
Watson Biologics has signed an amendment to broaden the scope of its research, development, and commercialization efforts for 'Core Flora Therapy' in the realms of precision microecological health and functional nutritional intervention. This amendment grants the company exclusive rights to develop, manufacture, and market this technology for non-patient populations within mainland China, Hong Kong, and Macau. Additionally, it revises the financial terms, duration, and due diligence clauses of the agreement. Notably, this amendment is not expected to significantly influence the company's operating performance for the current fiscal year.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
